Review Article
Comprehensive Review of Hypertensive Disorders Related to Pregnancy
Abstract
Hypertensive disorder of pregnancy is a common complication during pregnancy that affects approximately 10% of pregnancies and is responsible for nearly 14% of maternal deaths worldwide. It affects the mother and the fetus simultaneously, sometimes putting the health of the mother and the fetus at odds with each other. It may present with only hypertension and proteinuria or with life-threatening complications in the mother such as eclampsia; stroke; acute pulmonary edema; acute renal failure; disseminated intravascular coagulation; placental abruption; hemolysis, elevated liver enzymes, and low platelet syndrome; pregnancy loss; and fetal growth restriction and prematurity resulting from the frequent need of delivering preterm in the fetus. In this review, we aimed to describe hypertensive disorders of pregnancy, mainly preeclampsia and chronic hypertension in pregnancy, by discussing the pathophysiology, the central role of abnormal placentation, the release of antiangiogenic factors in the circulation and immunological factors, the clinical outcome in the mother and the fetus, and the diagnostic criteria and principles of management of both the conditions. We also discuss possible screening methods and prevention of preeclampsia using low-dose aspirin and eclampsia prophylaxis.Posted in: Hypertension17 Pregnancy32
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Roberts JM, August PA, Bakris G. Hypertension in pregnancy. Obstet Gynecol 2013;122:1122–1131.
2. Main EK, McCain CL, Morton CH, et al. Pregnancy-related mortality in California: causes, characteristics, and improvement opportunities. Obstet Gynecol 2015;125:938–947.
3. Kanata M, Liazou E, Chainoglou A, et al. Clinical outcomes of hypertensive disorders in pregnancy in the offspring during perinatal period, childhood, and adolescence. J Hum Hypertens 2021;35:1063–1073.
4. Wang W, Xie X, Yuan T, et al. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population-based study. BMC Pregnancy Childbirth 2021;21:364.
5. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014;2:e323–e333. .
6. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565.
7. English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control 2015;8:7–12.
8. Cartwright JE, Fraser R, Leslie K, et al. Remodelling at the maternal-fetal interface: relevance to human pregnancy disorders. Reproduction 2010; 140:803–813.
9. Lim KH, Zhou Y, Janatpour M, et al. Human cytotrophoblast differentiation/ invasion is abnormal in pre-eclampsia. Am J Pathol 1997;151:1809–1818.
10. Burton GJ, Redman CW, Roberts JM, et al. Pre-eclampsia: pathophysiology and clinical implications. BMJ 2019;366:l2381.
11. Brosens I, Pijnenborg R, Vercruysse L, et al. The “great obstetrical syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 2011;204:193–201.
12. Oggè G, Romero R, Kusanovic JP, et al. Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. J Matern Fetal Neonatal Med 2010;23: 820–827.
13. Ives CW, Sinkey R, Rajapreyar I, et al. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review. J Am Coll Cardiol 2020;76:1690–1702.
14. Wallace AE, Fraser R, Cartwright JE. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Hum Reprod Update 2012;18: 458–471.
15. Kalkunte SS, Mselle TF, Norris WE, et al. Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J Immunol 2009;182:4085–4092.
16. Anacker J, Segerer SE, Hagemann C, et al. Human decidua and invasive trophoblasts are rich sources of nearly all human matrix metalloproteinases. Mol Hum Reprod 2011;17:637–652.
17. Du M, Wang W, Huang L, et al. Natural killer cells in the pathogenesis of preeclampsia: a double-edged sword. J Matern Fetal Neonatal Med 2022; 35:1028–1035.
18. Campos-Cañas J, Romo-Palafox I, Albani-Campanario M, et al. An imbalance in the production of proinflammatory and anti-inflammatory cytokines is observed in whole blood cultures of preeclamptic women in comparison with healthy pregnant women. Hypertens Pregnancy 2014;33: 236–249.
19. Fan DM, Wang Y, Liu XL, et al. Polymorphisms in interleukin-6 and interleukin-10 may be associated with risk of preeclampsia. Genet Mol Res 2017 February 23;16.
20. Nath MC, Cubro H, McCormick DJ, et al. Preeclamptic women have decreased circulating IL-10 (interleukin-10) values at the time of preeclampsia diagnosis: systematic review and meta-analysis. Hypertension 2020;76:1817–1827.
21. Phipps EA, Thadhani R, Benzing T, et al. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 2019;15:275–289.
22. Girardi G, Prohászka Z, Bulla R, et al. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol Immunol 2011;48:1621–1630.
23. Rampersad R, Barton A, Sadovsky Y, et al. The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta 2008; 29:855–861.
24. Pankiewicz K, Szczerba E, Maciejewski T, et al. Non-obstetric complications in preeclampsia. Prz Menopauzalny 2019;18:99–109.
25. Adekomi AD, Moodley J, Naicker T. Neuropathological complications associated with hypertensive disorders of pregnancy. Hypertens Pregnancy 2019;38:171–175.
26. Armaly Z, Jadaon JE, Jabbour A, et al. Preeclampsia: novel mechanisms and potential therapeutic approaches. Front Physiol 2018;9:973.
27. Wilkerson RG, Ogunbodede AC. Hypertensive disorders of pregnancy. Emerg Med Clin North Am 2019;37:301–316.
28. Mendola P, Mumford SL, Männistö TI, et al. Controlled direct effects of preeclampsia on neonatal health after accounting for mediation by preterm birth. Epidemiology 2015;26:17–26.
29. Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126: 443–456.
30. Barker DJ. Fetal origins of coronary heart disease. BMJ 1995;311:171–174.
31. Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989;321:357–362.
32. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017;377:613–622.
33. George EM, Granger JP. Mechanisms and potential therapies for preeclampsia. Curr Hypertens Rep 2011;13:269–275.
34. Samangaya RA, Mires G, Shennan A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009;28:369–382.
35. Trapani A Jr, Goncalves LF, Trapani TF, et al. Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: a randomized controlled trial. Obstet Gynecol 2016;128:253–259.
36. Cormick G, Betrán AP, Romero IB, et al. Global inequities in dietary calcium intake during pregnancy: a systematic review and meta-analysis. BJOG 2019;126:444–456.
37. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183:S1–S22.
38. August P. Preeclampsia: new thoughts on an ancient problem. J Clin Hypertens (Greenwich) 2000;2:115–123.
39. Vidaeff A, Espinoza J, Simhan, et al. Gestational hypertension and preeclampsia. Obstet Gynecol 2020;135:e237–e260.
40. Brown CM, Garovic VD. Drug treatment of hypertension in pregnancy. Drugs 2014;74:283–296.
41. Kattah AG, Garovic VD. The management of hypertension in pregnancy. Adv Chronic Kidney Dis 2013;20:229–239.
42. Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet Gynecol 1986;67:517–522.
43. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009;374:979–988.
44. Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Am J Obstet Gynecol 2011;205:191–198.
45. Blackwell SC, Redman ME, Tomlinson M, et al. Labor induction for the preterm severe pre-eclamptic patient: is it worth the effort? J Matern Fetal Med 2001;10:305–311.
46. Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trial. Lancet 2002;359:1877–1890.
47. Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases. Am J Obstet Gynecol 1984;148:951–963.
48. McCubbin JM, Sibai BM, Ardella TN, et al. Cardiopulmonary arrest due to acute maternal hypermagnesaemia. Lancet 1981;1:1058.
49. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia. Clin Pharmacokinet 2000;38:305–314.
50. Panaitescu AM, Syngelaki A, Prodan N, et al. Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol 2017;50:228–235.
51. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043–2050.
52. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
53. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation 2014; 129:1254–1261.
54. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics —2011 update: a report from the American Heart Association. Circulation 2011;123:e18–e209.
55. Lawler J, Osman M, Shelton JA, et al. Population-based analysis of hypertensive disorders in pregnancy. Hypertens Pregnancy 2007;26:67–76.
56. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol 2002;100: 369–377.
57. Zetterström K, Lindeberg SN, Haglund B, et al. Maternal complications in women with chronic hypertension: a population-based cohort study. Acta Obstet Gynecol Scand 2005;84:419–424.
58. Moussa HN, Alrais MA, Leon MG, et al. Obesity epidemic: impact from preconception to postpartum. Future Sci OA 2016;2:FSO137.
59. Puar TH, Mok Y, Debajyoti R, et al. Secondary hypertension in adults. Singapore Med J 2016;57:228–232.
60. Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician 2017;96:453–461.
61. Guedes-Martins L. Chronic hypertension and pregnancy. Adv Exp Med Biol 2017;956:395–407.
62. Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013;61:932–942.
63. Sibai BM, Chames MC. Chronic hypertension in pregnancy. Glob Libr Womens Med 2008;doi: 10.3843/GLOWM.10156.
64. Vanek M, Sheiner E, Levy A, et al. Chronic hypertension and the risk for adverse pregnancy outcome after superimposed preeclampsia. Int J Gynaecol Obstet 2004;86:7–11.
65. Sibai BM. Diagnosis and management of chronic hypertension in pregnancy. Obstet Gynecol 1991;78(3 Pt 1):451–461.
66. Vidaeff A, Espinoza J, Simhan H, et al. Chronic hypertension in pregnancy. Obstet Gynecol 2019;133:e26–e50.
67. Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018;10:CD002252.
68. Magee LA, Singer J, von Dadelszen P, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015;372:2367–2368.
69. Tita AT, Szychowski JM, Boggess K, et al. Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for mild chronic hypertension during pregnancy. N Engl J Med 2022;386:1781–1792.
